{
    "clinical_study": {
        "@rank": "84171", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the long-term effectiveness of naltrexone\n      treatment in alcohol-dependent patients who respond to short-term treatment.  Those who\n      respond to short-term treatment will be randomized to a 1-year, double-blind,\n      placebo-controlled maintenance phase with a 6-month posttreatment followup."
        }, 
        "brief_title": "Naltrexone Maintenance Treatment of Alcoholism", 
        "completion_date": "April 2002", 
        "condition": "Alcoholism", 
        "condition_browse": {
            "mesh_term": "Alcoholism"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Meets criteria for alcohol dependence.\n\n          -  Expresses a desire to cut down or stop drinking.\n\n        Exclusion Criteria:\n\n          -  Currently meets criteria for dependence on substances other than alcohol.\n\n          -  History of opiate dependence or evidence of current opiate use.\n\n          -  Significant medical disorders that will increase potential risk or interfere with\n             study participation.\n\n          -  Liver function tests more than 3 times normal or elevated bilirubin.\n\n          -  Female patients who are pregnant, nursing, or not using a reliable method of birth\n             control.\n\n          -  Inability to understand and provide a consent form.\n\n          -  Treatment with an investigational drug during the previous month.\n\n          -  Prior treatment with naltrexone.\n\n          -  Chronic treatment with any narcotic-containing medications during the previous month.\n\n          -  Sensitivity to naltrexone as evidenced by adverse drug experiences especially with\n             narcotic containing analgesics or opioid antagonists.\n\n          -  Current treatment with disulfiram.\n\n          -  More than 6 weeks of abstinence.\n\n          -  Meets criteria for a major psychiatric disorder and is in need of, or currently\n             undergoing pharmacotherapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "184", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000450", 
            "org_study_id": "NIAAAMAS10518", 
            "secondary_id": "R01AA010518"
        }, 
        "intervention": {
            "intervention_name": "naltrexone (Revia)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Naltrexone"
        }, 
        "lastchanged_date": "July 21, 2010", 
        "location": {
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33136"
                }, 
                "name": "Department of Psychiatry, University of Miami School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Nalmefene Maintenance Treatment of Alcoholism", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 4", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000450"
        }, 
        "source": "The Scripps Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "The Scripps Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2010"
    }, 
    "geocoordinates": {
        "Department of Psychiatry, University of Miami School of Medicine": "25.789 -80.226"
    }
}